Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of PRM-151 in myelofibrosis
2015-001718-80Phase 2Completed
- Sponsor
- Promedior
- Start
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of zinpentraxin alfa in primary myelofibrosis (PMF) and myelofibrosis (MF) (3 arms), sponsored by Promedior. Primary endpoint: Bone marrow response rate. Started Jul 2015; status: completed.
02
Drugs
zinpentraxin alfa
03
Conditions
primary myelofibrosis (PMF)myelofibrosis (MF)
Beyond the preview
Go deeper on 2015-001718-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001718-80.